EVMN

Evommune is a clinical-stage biotech that only began trading on the NYSE on November 6, 2025, and the financials make clear this is a research operation, not a business. FY2025 'revenue' of $13.0M is almost certainly collaboration/license income — the MD&A repeatedly flags the company's 'need to raise additional funding before we can expect to generate any revenues from product sales,' and the entire forward narrative hinges on two unapproved candidates, EVO756 and EVO301. Operating losses of -$81.1M on that $13.0M base produce a nonsensical -624% operating margin, and R&D alone ($74.0M) is nearly 6x revenue. The -$221M accumulated deficit confirms this is a cash-burn story from inception.

The balance sheet is the single biggest red flag. Cash & equivalents stand at just $44.1M against FY2025 operating cash burn of -$76.4M — that is well under one year of runway at the current pace, and burn is accelerating (OCF deteriorated 31.4% YoY). Total assets jumped 195.8% and equity 242.5% YoY almost entirely because of IPO proceeds raised late in the fiscal year, yet even after the raise the company is already structurally undercapitalized. The new 32,016 sq ft Palo Alto lease commencing March 2026 (tripling their footprint) and the New York office through 2030 commit Evommune to a higher fixed-cost base precisely as cash dwindles — another dilutive secondary is essentially a certainty within 12 months.